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Animal Models in Psychiatric 
Disorder Studies
João Victor Nani, Benjamín Rodríguez, Fabio Cardoso Cruz 
and Mirian Akemi Furuie Hayashi
Abstract
Among the diseases affecting the brain, special attention has been paid to 
psychiatric disorders (PDs) due to high prevalence and significant debilitating 
clinical features. Many difficulties need to be overcome to find good animal models 
for PDs, due to their multifactorial origins, high heterogeneity and symptoms, 
as for instance the hallucinations and delusions, which usually cannot be easily 
assessed employing ordinary experimental animal models. The use of animal 
models reproducing at least some specific traits that can be studied individually, 
known as endophenotypes, is often reported. However, since altered biological 
pathways are common to many of these disorders, each of these behaviors may also 
reflect different PDs. In this context, it is possible to perform several approaches, 
to elicit changes in the endophenotypes of interest, not only in vertebrate models 
like rodents, but also in invertebrate models which have important advantages due 
to high conservation of essential pathways, lower complexity, and shorter life cycle 
compared to mammals. Therefore, animal models are also helpful for elucidating 
the etiology underlying PDs, by allowing easier access to biological samples that are 
usually not accessible in clinical studies, as for instance, fresh brain samples, from 
embryos to adults.
Keywords: animal model, psychiatric disorders, neurodevelopment, biomarkers, 
CNS, endophenotypes
1. Introduction
According to the World Health Organization (WHO), psychiatric disorders 
(PDs) comprise a broad range of dysfunctions, with several and some common 
symptoms. PDs are generally characterized by the combination of symptoms as 
abnormal thoughts, emotions, behavior, and social interaction. The most common 
PDs include schizophrenia (SCZ), bipolar disorder (BD), major depression disorder 
(MDD), attention deficit hyperactivity disorder (ADHD), intellectual disabilities, 
drug abuse disorders, among others [1].
1.1 The need and the value of animal models for PD studies
There are several reasons to use animal models in the studies of disorders affect-
ing the brain. The poor understanding of the etiopathogenesis and pathophysiology 
of PDs is clearly reflected by the unmet clinical need for better pharmacological 
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treatments. Therefore, good models are clearly needed to clarify the neurobiol-
ogy involved in PDs, as well as for the identification of biomarkers useful to assist 
diagnosis and/or for the development of novel therapies. It is also implausible to 
move forward in clinical trials with a novel drug tested only in a cell model, without 
any evidence about its efficacy in animal experiments. The value of animal models 
to drug development has been demonstrated empirically. For example, the first 
and the most efficacious drugs available for complex PDs such as SCZ (e.g., chlor-
promazine and clozapine) was discovered observing the alterations in behaviors of 
experimental animals in response to each drug administration. In fact, in the last 
decades, most of the CNS drugs approved were discovered employing a phenotypic 
screening approach in animal models [2, 3].
1.2 Challenges to model PDs in animals
A reliable animal model must share several similarities with the studied target 
to allow a successful translation from the basic to the clinical research. However, 
several limitations need to be overcome. First, the heterogeneous behavioral symptom 
characteristics of PDs are in some grade uniquely expressed in humans, and they are 
certainly impossible to be reproduced authentically in animals as rodents, fishes or 
worms [4]. Second, there is a lack of an objective measure to unequivocally diagnose 
mental illness [5], which adds complexity to the modeling any mental disorder in 
experimental animals. Third, in order to develop meaningful animal models for PDs 
with potential translational power, the disease phenotypes must be represented in the 
experimental animals. The selection and update of these phenotypes, in agreement 
with the recent findings in clinical psychiatry and neuroscience, represents a chal-
lenge, as evidenced by the recognized gap between the clinical and basic scientific 
research [6]. In addition, a rising question is what are the specific traits or phenotypes 
that an animal model should express to be translatable to specific disorder? (Figure 1).
1.3 How to develop an animal model for PD studies
The traditional approach to establish an animal model in PDs is based on three 
classic constructs proposed by Willner in 1984: face validity, which determines how 
much a phenotype presented by a patient is represented by the animal model (corre-
sponds to similarity between the model and the PDs assessed, that includes symp-
toms, signs, and pharmacological features); construct validity, which demonstrates 
whether it is possible to reproduce the pathological condition based on processes that 
are already known to be altered (correspondence between the physiological dysfunc-
tions in the human population and in the animal model); predictive validity, which 
tries to evaluate if a pharmacological or non-pharmacological intervention is capable 
to reverse the pathological condition (in other words, if the treatment that is effec-
tive in reversing PDs in humans would reverse the changes seen in animals) [7–10]. 
However, in practice, no animal models fully meet these three criteria of validity.
Many authors have proposed that instead of these three proposed criteria 
defining an external validation, in addition, the validity of an animal model 
should not be simply organisms that resemble human dysfunction, but they would 
also reproduce the processes by which animals and humans enter this state, and 
therefore, this could be better exploited by adding a new validation criteria [9]. For 
instance, the validity by homology, which proposes, for instance, an invertebrate 
model, such as Drosophila, may not be the ideal animal model for studying complex 
changes in a brain circuitry, but in turn, it may represent a great choice to study 
the genetic control of early embryonic development [11]. In fact, the nematode 
Caenorhabditis elegans is a reliable model with conserved neurobiological systems 
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that has been helpful in the discovery of molecular mechanisms that underlie learn-
ing and memory, and, in addition, this animal model has a fully sequenced genome 
and other several molecular and genetic tools available for researchers [12, 13].
1.4 Symptoms versus endophenotypes in experimental model animals
There is a consensus about the low reliability of the diagnostic construct provided 
for the employment of Diagnostic and Statistical Manual of Mental Disorders or DMS 
(which is a manual that determines the criteria for the clinical diagnosis of PDs). The 
heterogeneity implicit in this classification system and the imprecise quantification 
of the symptoms make it impossible to deconstruct PDs within model organisms. In 
fact, an etiology-based nosology system has been advocate for psychiatry, and it has 
been proposed to identify the endophenotypes that occur in both healthy individuals 
and subjects with different psychopathologies [14]. Endophenotypes are basically 
quantitative trait-like deficits that are possible to assess by laboratory-based methods 
rather than by clinical observation. An endophenotype should be state-independent, 
heritable, occurring at a high rate in affected families, and in addition, it should be 
associated to genetic variants of the disorder, as it should be involved the same brain 
circuits associated with the symptoms of the illness in patients (Table 1).
The Research Domains Criteria (RDoC) framework was introduced as an alterna-
tive categorization system for psychopathological states [15–17]. This system provides 
a platform to improve the translatability of studies from animals to humans, since it 
supports the endophenotype-based comparison of animals and humans on an objec-
tive neurobiological basis across all behavioral domains. In fact, the endophenotypes 
have been reverse-translated into animal models successfully and allows the evaluation 
Figure 1. 
Different approaches to construct animal models for neuropsychiatric disorders studies.
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of the neural neurobiological substrates and their circuit dysfunctions [18]. Thus, it 
has been demonstrated that the modeling of neurobiological and behavioral endophe-
notypes to reproduce PDs in experimental animals is possible.
The ideal animal model should be derived from risk factors or the causative 
agent of the human disease. One of the strategies used during the construction of a 
model is focused on a specific factor that can reproduce the condition as a whole or 
an aspect of the disease [19]. The choice for the methodology used in establishing 
a model is fundamentally important to guide which aspect of the disease should be 
explored, and it is an essential component in the validation of a model known as 
construct validity.
Endophenotype Description What can be evaluated
Locomotor activity Distance travelled, time spent, and frequency 
of the movements measured during or after a 
habituation period or after some stimuli (i.e. 
drug administration)
Behavioral sensitization (BD; 
ADHD; SCZ); Depressive-like 
behaviors (MDD); etc…
Latent inhibition Latent inhibition is the ability of a pre-exposed 
nonreinforced stimulus to inhibit later stimulus-
response learning
Cognitive impairments 
(SCZ); etc…
Pre-pulse inhibition 
(PPI)
Decrease of the startle reflex after exposure to a 
pre-pulse before the pulse
Cognitive impairments 
(SCZ); etc…
Working memory 
and learning
Describes short-term memory, in a olfactory 
domain and spatial domain
Cognitive impairments  
(PDs in general); etc…
Social interaction Evaluation of time spent on exploring a social 
stimulus.
Anxiety-like behaviors; 
Depressive-like behaviors; 
etc…
Rearing Measure of activity, investigation and 
exploratory behavior induced by a drug or/and 
novelty
Anxiety-like behaviors; etc…
Grooming A maintenance behavior evaluated by the 
cleaning of the fur; is displayed as reaction to 
unexpected stimuli and in conflict situations
Anxiety-like behaviors; 
Depressive-like behaviors; 
etc…
Aggressiveness Evaluation of attack and defensive behavior as 
reaction to a stimuli or other animal
Anxiety-like behaviors; 
Depressive-like behaviors; 
etc…
Food intake Amount of food ingested by the animal Anxiety-like behaviors; 
Depressive-like behaviors; 
etc…
Sucrose preference 
test
Assesses the sensitivity to reward based on the 
rodent’s natural preference for sweets. This test 
measures the amount of a sweet-tasting solution 
that the animal ingests
Depressive-like behaviors; 
etc…
Fear conditioning Classical conditioning paradigm, in which an 
aversive stimulus is paired with some neutral 
stimuli. Used to assess associative fear learning 
and memory in rodents.
Cognitive impairments (PDs 
in general); etc…
Forced swim test Measures the scoring of swimming and 
climbing (active behavior), and immobility 
(passive behavior) when animals are placed in 
an inescapable cylinder filled with water
Depressive-like behaviors; 
etc…
Table 1. 
Most common endophenotypes used to evaluate behaviors associated with psychiatric disorders (PDs).
5Animal Models in Psychiatric Disorder Studies
DOI: http://dx.doi.org/10.5772/intechopen.89034
2. PDs and animal models
In the following sections, selected examples of animal models used in the 
context of investigating PDs will be demonstrated, indicating which changes are 
observed in behavioral and molecular levels.
2.1 Animal models in schizophrenia (SCZ)
Schizophrenia (SCZ) is a severe brain disorder, characterized by a set of 
positive and negative symptoms and cognitive disorders, which are the basis for 
the clinical diagnosis of individuals who needs to present at least two or more 
of those symptoms, according to the DSM. SCZ is one of the most debilitating 
mental disorders, affecting about 21 million people worldwide. The antipsychot-
ics used to treat SCZ patients can soften the development of the disorder, and 
this pharmacological treatment was the basis for the most accepted theory to 
explain the neurobiology of SCZ, as noticed by the alterations in the dopamine 
transmission. In addition, several other theories have been suggested soon after, 
as for instance, the serotoninergic, glutamatergic, GABAergic, and the neuro-
developmental susceptibility hypothesis, among others [20]. However, none of 
these theories had allowed the characterization of the etiology or the identifica-
tion of strong biomarker for the diagnosis of SCZ. Many efforts are being made 
to characterize a model for SCZ, but there is a great difficulty in reproduce 
endophenotypes that frame all the groups of symptoms related to this disease, or 
which allow associating all risk factors that are already known. Below, we exem-
plify some of these models, and for a more detailed review of SCZ models can be 
found elsewhere [21].
Most of the models are based on the theory of neurotransmitter imbalance, 
and they are induced by the disruption of these pathways, other models explore 
changes in the levels of expression of candidate genes involved in the processes of 
SCZ susceptibility. It should be considered that SCZ is a multifactorial disorder, 
and thus, the genetic component should be evaluated in addition to changes in the 
environment, as in contrast to the models based on genetic alterations, there are 
those taking into account the environmental changes, such as the prenatal insults, 
which impose changes in the neurodevelopment processes. Some of these models 
are exemplified in Table 2.
All of these models show behavioral and molecular changes that can be associ-
ated with SCZ.
2.2 Animal models in major depressive disorder (MDD)
Major depressive disorder (MDD) is a common, complex, and heterogeneous 
mental disorder, characterized by persistent sadness and loss of interest in general 
activities, affecting about 10% of the population worldwide, and which is caused 
by multifactorial mechanisms not fully understood yet,  characterizing MDD as 
a disorder with many variations in clinical features among the patients, impos-
ing a consequent high variability in the diagnosis, time course of response and 
remission [45], which is one of the main reasons justifying the intensive search for 
animal models and biomarkers, aiming for advances in MDD diagnosis [46]. In 
addition, these advances could be helpful for a better classification for depressive 
spectrum, and thereby for improving the treatment [47]. The animal models of 
depression have been developed based on acute or chronic stress exposure, exog-
enous administration of glucocorticoids, injuries in brain regions and/or genetic 
manipulations [48–50]. There is a great variation in the number of protocols that 
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Model Endophenotype Molecular alterations References
Drug-induced models
Amphetamine model of 
SCZ
Acute:
↓ Latent inhibition;  
↑ locomotion
Chronic:
Same as acute but with 
↓ PPI
↑ Mesolimbic dopamine 
response;
↑ Acetilcholine in PFc
[22–26]
Glutamatergic manipulation 
(Phencyclidine; MK-801; 
Ketamine)
↑ Locomotion; ↓ working 
memory;
↓ Reversal learning 
performance;
↓ Social interaction; ↓ PPI
↓ PV-immunoreactive 
neurons in PFc and 
hippocampus
[27–29]
Genetic manipulation
DISC-1 mutations
Missense mutations models ↓ PPI; ↓ latent inhibition;
↑ Depressive-like 
phenotype
↓ Brain volume;
↓ PDE4B activity and 
binding to DISC1;
↓ PV-immunoreactive;
↓ Dendritic density
[30–32]
Dominant-negative 
isoforms of DISC1
↑ Amphetamine sensibility; 
↓ working memory
↓ Dopamine, DOPAC;
↓ PV-immunoreactive
[33, 34]
Knockdown ↑ Amphetamine sensibility; 
↓ PPI; ↓ working memory
↓ Dopamine;  
↓ PV-immunoreactive
[35]
Overexpression ↑ Amphetamine sensibility; 
↑ rearing behavior;  
↑ locomotion; ↓ learning in 
rotarod task
↑ Increase in high-
affinity D2R;
↑ Translocation of 
dopamine transporter;
↑ Dopamine inflow
[36]
Neuregulin1, ErbB4, and dysbindin
Knock-out ↑ Amphetamine sensibility; 
↑ locomotion; ↓ PPI;
↓ Working memory;  
↓ social interaction
Neuregulin1; ErbB4:
↓ Hippocampal spine 
density;
↑ Lateral ventricles;
Dysbindin:
↑ HVA/DA ratio;
↑ Excitability of PFc 
pyramidal neurones
[37–39]
Developmental models
Neonatal excitotoxic 
hippocampal lesion
↓ PPI; ↓ Working memory; 
↓ Social interaction;  
↑ Amphetamine sensibility; 
↑ MK-801/PCP sensibility; 
↑ locomotion
↑ Mesolimbic dopamine 
response;
↑ Acetilcholine in PFc
[40, 41]
Methylazomethanol 
(MAM) and polyinosinic-
polycytidylic acid (poly I:C)
↑ Locomotion;
↑ Amphetamine sensibility; 
↑ MK-801/PCP sensibility; 
↓ Social interaction; ↓ PPI; 
↓ Working memory
↓ PV-immunoreactive 
neurons in PFc and 
hippocampus
[42–44]
All of these models show behavioral and molecular changes that can be associated with SCZ.
PPI = prepulse inhibition; PFc = prefrontal cortex; PV = parvalbumin; PDE4B = cAMP-specific 3",5"-cyclic 
phosphodiesterase 4B; DISC1 = disrupted-in-schizophrenia 1; DOPAC = dihydroxyphenylacetic acid; HVA = 
homovanillic acid; DA = dopamine; poly I:C = Polyinosinic:polycytidylic acid.
Table 2. 
Some examples of SCZ models induced by drugs, genetic manipulation, and prenatal insults.
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can be used to induce these changes, in which the stressor, time of exposure to 
the stimulus, and other parameters may vary. For more detailed review of MDD 
models, see also [51] (Table 3).
Model Endophenotype Molecular alterations References
Stress-induced models
Learned 
Helplessness
↓ Locomotion;  
↑ aggressiveness
↓ Grooming; ↓ response to 
rewards
↑ Sleep disturbance
↓ Norepinephrine ; ↑ BDNF; 
aberrant miRNA brain- region 
specific expression
[52–57]
Unpredictable 
chronic mild 
stress
↓ Food intake;  
↓ growth rate;
↓ Locomotion;  
↑ aggressiveness;
↓ Response to rewards
↑ Corticosterone; ↓ glucocorticoid 
receptor expression;  
↓ endogenous ATP
[58–61]
Chronic restraint 
stress model
↑ Aggressiveness;  
↑ fear conditioning;  
↓ locomotion; ↓ food 
intake
↑ CA3 dendritic atrophy and 
damage; ↓ neurogenesis in dentate 
gyrus; ↑ apoptotic cell death;  
↑ corticosteroid
[62–64]
Social defeat ↓ Locomotion; ↓ 
exploratory activity;
↓ Aggression; ↓ sexual 
behavior;
↑ Anhedonia; ↑ sleep 
disturbance ;
↓ Growth rate
↓ Volume and cell proliferation in 
hippocampus and PFc;  
↑ corticosteroid; ↓ serotonin;  
↓ BDNF
[65–67]
Early life stress 
model
↑ Anxiety-like behavior;
↑ Depression-like 
behavior; ↑ Novelty 
responsivity
↑ BDNF expression PFC and 
hippocampus
[68, 69]
Brain lesion model
Olfactory 
bulbectomy
↑ Locomotion; ↓ working 
memory; ↓ response to 
rewards; ↓ food intake; 
↑ sleep disturbance; ↑ 
responsivity to stressors
Dysfucntion in HPA and  
neuro-immune axis;  
↓ neurotransmitters; ↑ neuronal 
degeneration; ↑ BDNF;  
↓ neuropeptides
[70, 71]
Selective inbreeding
Wistar-Kyoto ↓ Locomotion; ↑ 
immobility in forced swim 
test; ↑ social avoidance;
↑ freezing to context
↑ Adrenal glands; ↑ corticosterone [72, 73]
Flinders Sensitive 
Line rat
↓ Activity in enclosed 
arena;
↑ immobility in forced 
swim test;
↓ sucrose intake under 
stress
↓ Serotonin synthesis; 
dysfunction in dopaminergic and 
noradrenergic systems
[74–77]
BDNF = brain-derived neurotrophic factor; miRNA = microRNA; ATP = adenosine triphosphate; PFc = prefrontal 
cortex; HPA = hypothalamic–pituitary–adrenal axis.
Table 3. 
Examples of models for MDD induced by stressors, injuries in brain regions, and by selective inbreeding.
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2.3 Animal models in bipolar disorder (BD)
Bipolar disorder (BD) is a chronic mood disorder, characterized by fluctua-
tions between mania and depressive episodes, which affects approximately 1% of 
the global population irrespective of nationality, ethnic origin, or socioeconomic 
status [78]. Due to the complex mood alterations, misdiagnosis in BD is very 
common, as other mental illnesses as depression and SCZ share several common 
symptoms, in addition to the specific and common endophenotypes and brain 
structural changes [79, 80]. The search for advances in diagnosis is important for 
these disorders, since early diagnosis would be essential to foster earlier suited 
pharmacological treatment in BD, which was proved to be beneficial to prevent the 
cognitive deficits and disabilities in these BD patients [81], as also demonstrated 
for SCZ patients [82]. The major limitation in evaluating a model for BD is the dif-
ficulty in reproducing the phases of mania and depression observed in the clinic. 
Many of these models present only one of these parameters, and they are often 
developed by genetic alterations in genes known to be involved in this disorder or 
stressors, mainly involved in the circadian cycle as also demonstrated for other 
PDs. Another interesting approach used for the development of animal models for 
BD is the one induced by psychostimulant sensitization (which causes mania-like 
behavior), as withdrawal from psychostimulants is accompanied by depressive-
like behavior, which together leads to changes and compulsory behaviors. Some of 
these models are exemplified in Table 4. A more detailed review of BD models can 
be found elsewhere [93].
BDNF = brain-derived neurotrophic factor; ERK1 = Extracellular signal-regulated 
kinase 1; DAT = dopamine transporter.
Model Endophenotype Molecular alterations References
Genetic manipulation
BDNF haploinsufficient ↑ Locomotion; ↑ agressive 
behavior; ↑ food intake
↓ Brain volume; ↓ BDNF; 
↓ dopamine
[83, 84]
ERK1 Knock-out ↑ Amphetamine 
sensibility; ↓ learing in fear 
conditioning; ↑ locomotion; 
↓ immobility in forced swim
↓ Phospho-RSK1/3 in 
PFC and striatum;
shift of activity rhythm
[85–86]
DAT Knock-down ↑ Locomotion; ↓ anxiety;  
↑ rearing
↑ Dopamine [87–89]
Environmental stress
Sleep deprivation ↑ Locomotion; ↑ agressive 
behavior; ↑ exploratory 
behavior
— [90, 91]
Photoperiod lenghts ↑ Anxiety; ↑ helplessness Switch in dopamine 
neurotransmission to 
somatostatin
[92]
Sensitization model
Chronic amphetamine 
administration followed 
by withdrawal
↑ Locomotion; ↑ anxiety;  
↑ anhedonia; ↓ motivation;  
↓ working memory
↓ Dopamine 
responsiveness
↑ serotonin sensitivty
[94–96]
BDNF = brain-derived neurotrophic factor; ERK1 = Extracellular signal-regulated kinase 1; DAT = dopamine 
transporter.
Table 4. 
Examples of models for BD induced by genetic manipulation, environmental stressors, and induced by 
sensitization, which lead to some aspects of molecular and behavioral changes related to BD.
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2.4 Animal models in attention-deficit/hyperactivity disorder (ADHD)
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental 
disorder, affecting approximately 2.2–2.8% of worldwide, with multifactorial 
inducement, as reflected by the heterogeneity found in this disorder, and as indi-
cated by the diversity in its psychiatric comorbidities [97]. This disorder is defined 
by inappropriate levels of attention deficits and/or hyperactivity behavior, which 
directly interfere with the normal life and functioning of an individual [98]. 
While there is no cure for ADHD, currently available treatments can help reducing 
the symptoms and improving the general functioning, although with a peculiar 
wide variability due to the clinically and scientifically difficulties to exactly 
determine the specificity and the origin of the symptoms [99]. As for other PDs, 
due to the high heritability, animal models for ADHD are mostly derived from 
genetic alterations or breeding selection or from neonatal insults that can lead to 
neurodevelopmental changes. Models related to dopaminergic neurotransmission 
are also important to evaluate ADHD, as also listed in Table 2, and which includes 
the administration of psychostimulants as amphetamine. A more detailed review 
on ADHD animal models can be found elsewhere [100] (Table 5).
3. Conclusion
There is a consensus about the critical role of animal models for the advance and 
understanding the functioning of brain and brain disorders, as well as for the devel-
opment of new treatments. However, it is important to use them judiciously and avoid 
the over interpretations derived for the findings, as it is noticeable that the results 
obtained on experimental animals are not necessarily confirmed in clinical studies.  
Model Endophenotype Molecular alterations References
Genetic manipulation
Spontaneously 
hypertensive rats
↓ Attention; ↑ motor 
impulsiveness
↑ Locomotion; ↑ 
exploratory behavior
↑ Dopamine
↓ Dopamine transporter 
1 expression
↓ Brain volume
[101–104]
Coloboma mouse mutant ↑ Locomotion; ↑ 
exploratory behavior; 
↑ amphetamine 
sensibility
↑ Noraedrenergic 
function
↓ Dopamine
↓ DOPAC and HVA
[105–108]
Neonatal insults
6-hydroxydopamine ↓ Working memory;  
↑ locomotion;
↑ Exploratory behavior
↓ Dopamine
↑ Dopamine receptor 4
↓ Serotonin transporter 
binding in striatum
[109–111]
Neonatal anoxia ↑ Locomotion;  
↑ exploratory behavior;  
↓ spatial memory
Transient changes in 
neurotransmitters
↑ Dopamine turnover
↓ Noraepinephrine and 
5-HIAA
↓ CA1 cell density
[112–114]
DOPAC = 3,4-Dihydroxyphenylacetic acid; HVA = Homovanillic acid; 5-HIIA = 5-Hydroxyindoleacetic acid.
Table 5. 
Examples of models for ADHD induced by genetic manipulation in susceptibility genes and selective inbreeding 
and by prenatal insults.
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As it has been shown, there are several approaches to obtain an animal model for 
studies in psychiatry, but there is still a limitation in reproducing all the conditions 
involved in the pathophysiology of the disorder, and it is extremely crucial to rec-
ognize this limitation. An alternative that has proved to be efficient is to direct the 
study to a specific symptom domain that can answer at least in part, the significance 
of these findings to concretely improve the knowledge in PDs, and thereby bring 
advances in treatment. The crisis of the classification system is evidenced in the 
diagnostic inflation in psychiatry, which adds complexity to the preclinical research 
and complicates the modeling of PDs within the available experimental laboratory 
animals. The recent and alternative approaches as the RDoC to study the brain and 
behavior are in a relative infancy, but promises bringing new perspectives in how 
models that can be improved to become indeed helpful to benefit the quality of life of 
patients with PDs.
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